{"doi":"10.26599/nr.2025.94907933","title":"Aliphatic alcohols-based modification strategy to balance efficacy and safety of cabazitaxel prodrug nanoassemblies","abstract":null,"journal":"Nano Research","year":2025,"id":611690,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1574477,"name":"Danping Wang","orcid":null,"position":1,"is_corresponding":false},{"id":1574478,"name":"Shengyao Xu","orcid":null,"position":2,"is_corresponding":false},{"id":1389787,"name":"Jinrui Liu","orcid":"0009-0005-8733-1826","position":3,"is_corresponding":false},{"id":1574479,"name":"Xianbao Shi","orcid":null,"position":4,"is_corresponding":false},{"id":453047,"name":"Zhonggui He","orcid":"0000-0002-5907-3875","position":5,"is_corresponding":false},{"id":1574480,"name":"Yinglei Zhai","orcid":null,"position":6,"is_corresponding":false},{"id":453050,"name":"Bingjun Sun","orcid":"0000-0001-7986-5434","position":7,"is_corresponding":false},{"id":1238325,"name":"Jin Sun","orcid":"0000-0001-6707-3763","position":8,"is_corresponding":false},{"id":91835,"name":"Ya Gao","orcid":"0000-0003-2244-7834","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Aliphatic alcohols-based modification strategy to balance efficacy and safety of cabazitaxel prodrug nanoassemblies","abstract":"Prodrug-based nanoassemblies have emerged as advanced carrier-free nanomedicines. These prodrugs typically consist of drug modules, response modules, and modification modules. The general role of modification modules is to modulate the self-assembly ability of the prodrugs. How to optimize the structure of modification modules for balanced efficacy and safety of high-toxicity chemotherapeutic drugs deserves to be further investigated. In this study, a modification strategy of aliphatic alcohols with various chain lengths (SC<sub>4</sub>, SC<sub>8</sub>, SC<sub>12</sub>, SC<sub>16</sub> and SC<sub>20</sub>) was carried out to design five cabazitaxel (CBZ) prodrugs. Among them, CBZ-SC<sub> </sub>NPs with shorter chain length (SC<sub>4</sub> and SC<sub>8</sub>) showed poor self-assembly stability. CBZ-SC<sub>12 </sub>NPs also failed to remain stable while the other two CBZ-SC<sub> </sub>NPs exhibited good stability. In turn, the drug release rate was hindered by the increasing chain length. CBZ-SC<sub>12 </sub>NPs caused kidney damage due to their high redox-sensitivity and rapid release rate during circulation. By contrast, CBZ-SC<sub> </sub>NPs with longer chain length (SC<sub>16</sub> and SC<sub>20</sub>) not only demonstrated superior stability with improved pharmacokinetic behavior, but also might solve the dilemma of dose-related toxicity caused by CBZ. Overall, these findings emphasized the importance of chain length in modification module to modulate the efficacy and safety of CBZ prodrug nanoassemblies.&nbsp;","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4413336432","authors":[],"funders":[],"total_grants":0,"fwci":0.6583,"citation_percentile":0.65757894,"influential_citations":0,"citation_trend":[{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.26599/nr.2025.94907933","host_type":"journal"},{"url":"https://doi.org/10.26599/nr.2025.94907933","host_type":"publisher"},{"url":"https://doaj.org/article/6bbf6bcd845d4c4498a49d7e25a767ef","host_type":"repository"}],"fields_of_study":["Innovative Microfluidic and Catalytic Techniques Innovation","Nanoparticle-Based Drug Delivery","Graphene and Nanomaterials Applications"],"mesh_terms":[],"keywords":["Prodrug","Cabazitaxel","Balance (ability)","Chemistry","Nanotechnology","Materials science","Medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T21:51:55.026939Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}